Accuracy of the Kattan nomogram across prostate cancer risk-groups

BJU International

Volumn 108, Issue 1, 2011, Pages 56-60

  Korets, Ruslan ^a   Motamedinia, Piruz ^a   Yeshchina, Olga ^a   Desai, Manisha ^a   McKiernan, James M ^a  

^a Herbert Irving Pavilion 11th Floor ^*  (United States)

Author keywords

nomograms; prediction tools; prostate cancer; risk classification

Indexed keywords

ACCURACY; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; KATTAN NOMOGRAM; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SURVIVAL TIME;

EPIDEMIOLOGIC METHODS; FORECASTING; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79959297534     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09838.x     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Ross PL, Gerigk C, Gonen M, et al,. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20: 82-8 (Pubitemid 34522545)
3. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71 (Pubitemid 28259189)
4. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
5. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 281-6 (Pubitemid 34787593)
6. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87 (Pubitemid 26072233)
7. Graefen M, Karakiewicz PI, Cagiannos I, et al,. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002; 20: 3206-12 (Pubitemid 34831516)
8. Greene KL, Meng MV, Elkin EP, et al,. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol 2004; 171: 2255-9 (Pubitemid 38625446)
9. Mitchell JA, Cooperberg MR, Elkin EP, et al,. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005; 173: 1126-31 (Pubitemid 40380517)
10. Yossepowitch O, Eggener SE, Bianco FJ Jr, et al,. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493-9; discussion 499 (Pubitemid 47030486)
11. Stephenson AJ, Scardino PT, Eastham JA, et al,. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-12
12. Berglund RK, Stephenson AJ, Cronin AM, et al,. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology 2009; 73: 1098-103
13. Thanigasalam R, Rasiah KK, Stricker PD, et al,. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU Int 2009; 105: 642-7
14. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E,. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 2006; 49: 666-74 (Pubitemid 43374728)
15. Cooperberg MR, Pasta DJ, Elkin EP, et al,. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-42 (Pubitemid 40675216)
16. Cooperberg MR, Broering JM, Carroll PR,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878-87
17. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5 (Pubitemid 30434268)
18. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H,. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-6 (Pubitemid 37254948)
19. Suardi N, Porter CR, Reuther AM, et al,. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008; 112: 1254-63 (Pubitemid 351429740)
20. Kattan MW, Shariat SF, Andrews B, et al,. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21: 3573-9 (Pubitemid 46594048)